Rivia, a Zurich, Switzerland-based startup specializing in AI-driven analytics and clinical trial data infrastructure for Biotechs, raised €3M in Seed funding.
The round was led by Speedinvest alongside Amino Collective and Nina Capital.
The company intends to use the funds to hire new teams across engineering and client services, advance product development, and strengthen its position as the unified data platform for biopharma clinical trials.
Led by CEO Erik Scalfaro and CTO Thiago Kieliger, Rivia is an AI-driven analytics and clinical trial data infrastructure for Biotechs. The company offers a platform that simplifies clinical trial data acquisition and understanding through interactive analytics and AI-driven data insights.
Rivia serves clients across Europe and the US.
FinSMEs
10/06/2024